Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
48 vs 24 Weeks of Vivitrol for Opioid Relapse & HIV Risk
NCT01882361Phase 3Completed
- Sponsor
- University of Pennsylvania
- Start
- Jun 2013
- Primary completion
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of naltrexone in opioid use disorder (OUD) (2 arms), sponsored by University of Pennsylvania. Primary endpoints: Opiate positive urine tests at 12 months and HIV injecting risk at 12 months. Started Jun 2013; status: completed.
02
Drugs
naltrexone
03
Conditions
opioid use disorder (OUD)
Beyond the preview
Go deeper on NCT01882361.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01882361.